BRAVELLE
LOE ApproachingBLASubcutaneousInjectable
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRAVELLE is a subcutaneous injectable biologic approved in 2002 by Ferring Pharmaceuticals under BLA designation. The specific indication and mechanism of action are not publicly detailed in available data, but the product is classified as an 'other biologic' modality. Patient population and clinical use case require additional clinical reference.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate stable or contracting team size, typical of LOE-approaching products. Career opportunities on this product are limited, with focus shifting toward retention and knowledge transfer rather than growth hiring.
Brand ManagerMedical Science Liaison
Worked on BRAVELLE at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.